Anaerobutyricum soehngenii Reduces Hepatic Lipogenic Pathways and Increases Intestinal Gluconeogenic Gene Expression in Metabolic-Dysfunction-Associated Steatotic Liver Disease (MASLD) Mice
Authors:
- Anne Linde MakAMAnne Linde Mak
- Quinten J. J. AugustijnQAQuinten J. J. Augustijn
- Clément J. F. HeymannCHClément J. F. Heymann
- Stefan HavikSHStefan Havik
- Xanthe VerdoesXVXanthe Verdoes
- Melany Rios-MoralesMRMelany Rios-Morales
- Laura A. BosmansLBLaura A. Bosmans
- Joanne VerheijJVJoanne Verheij
- Abraham S. MeijnikmanAMAbraham S. Meijnikman
- Patrick A. de JongePJPatrick A. de Jonge
- Hilde HerremaHHHilde Herrema
- Willem M. de VosWVWillem M. de Vos
Open Access
- 20 March 2024
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (6) , 3481
Abstract
Metabolic-dysfunction-associated steatotic liver disease (MASLD) is a growing health problem for which no therapy exists to date. The modulation of the gut microbiome may have treatment potential for MASLD. Here, we investigated Anaerobutyricum soehngenii, a butyrate-producing anaerobic bacterium with beneficial effects in metabolic syndrome, in a diet-induced MASLD mouse model. Male C57BL/6J mice received a Western-type high-fat diet and water with 15% fructose (WDF) to induce MASLD and were gavaged with A. soehngenii (108 or 109 colony-forming units (CFU) 3 times per week) or a placebo for 6 weeks. The A. soehngenii gavage increased the cecal butyrate concentrations. Although there was no effect on histological MASLD scores, A. soehngenii improved the glycemic response to insulin. In the liver, the WDF-associated altered expression of three genes relevant to the MASLD pathophysiology was reversed upon treatment with A. soehngenii: Lipin-1 (Lpin1), insulin-like growth factor binding protein 1 (Igfbp1) and Interleukin 1 Receptor Type 1 (Il1r1). A. soehngenii administration also increased the intestinal expression of gluconeogenesis and fructolysis genes. Although these effects did not translate into significant histological improvements in MASLD, these results provide a basis for combined gut microbial approaches to induce histological improvements in MASLD.Keywords
This publication has 63 references indexed in Scilit:
- Toxicological safety evaluation of live Anaerobutyricum soehngenii strain CH106Journal of Applied Toxicology, 2021
- Parabacteroides distasonis Alleviates Obesity and Metabolic Dysfunctions via Production of Succinate and Secondary Bile AcidsCell Reports, 2019
- Molecular pathways of nonalcoholic fatty liver disease development and progressionCellular and Molecular Life Sciences, 2018
- An insight into gut microbiota and its functionalitiesCellular and Molecular Life Sciences, 2018
- The Impact of Dietary Fiber on Gut Microbiota in Host Health and DiseaseCell Host & Microbe, 2018
- Gut microbiota derived metabolites in cardiovascular health and diseaseProtein & Cell, 2018
- Microbiota-Generated Metabolites Promote Metabolic Benefits via Gut-Brain Neural CircuitsCell, 2014
- Nonalcoholic Fatty Liver Disease (NAFLD) Activity Score and the Histopathologic Diagnosis in NAFLD: Distinct Clinicopathologic Meanings §ΔHepatology, 2010
- Lipin 1 is an inducible amplifier of the hepatic PGC-1α/PPARα regulatory pathwayCell Metabolism, 2006
- Design and validation of a histological scoring system for nonalcoholic fatty liver disease†Hepatology, 2005